Vetter on new pathways to further develop the injection process8 Jun 2018
Open Innovation Challenge to tackle how digital trends can be applied to enhance solutions for the injection of medicines.
How can digital trends be used purposefully in regards to the application of injection systems? That is the key question being addressed by Vetter’s Open Innovation Challenge. The purpose of the challenge is to develop innovative, future-focused and sustainable solutions for the injection of medicines that are even better streamlined to user needs than current methods. Promising ideas emanating from the initiative will be further pursued in the context of Vetter’s innovation process.
The challenge consists of multi-disciplinary teams participating in workshops and field-work with the theme ꞌInjection 2.0ꞌ. Four groups comprising a total of 20 participants will include students, medical and economic professionals, and staff from the pharmaceutical service provider itself. The initiative will apply ꞌDesign Thinkingꞌ, a user-centered innovation method that involves direct communication with actual users of injection systems, including professional caregivers and patients in an effort to create more purposeful injection processes. The campaign will continue until the end of September with the winning team receiving an award of EUR 10,000.
“As an innovative partner of the top 20 pharmaceutical and biotech companies worldwide, we feel it is our responsibility to introduce continuous improvements to the safety and comfort aspects of the injection process for users as well as enhancements to our service offering based around the injection of medicine. That is precisely what our Open Innovation Challenge is designed to do; benefit medical specialists and patients as well as offering our customers new and valuable insights,” said Dr. Claus Feussner, Senior Vice President Vetter Development Service.
To identify sustainable areas of innovation potential, the pharmaceutical service provider incorporates the Design Thinking method. The User-Centered Innovation (UCI) approach is based on direct integration of users from the first day of development work. For example, in the first field-work phase, participating teams will interview patients, doctors and professional caregivers in healthcare settings that include nursing homes, assisted living facilities, hospitals, and the home healthcare sector itself. The goal is to use this information to address patient’s conscious and subconscious needs and any problems that arise when interacting with injection systems on a regular basis. Based on these results, user-oriented ideas for solutions can be generated.
“In the future, the active integration of users into the pharmaceutical development process will take on increasing importance. Because most users have long since arrived in the digital world, they are expecting to see this megatrend applied to medical products as well. That is why we have been investing today for the future, as demonstrated by our Open Innovation Challenge. This initiative will not only strengthen our role as one of the world’s leading partners in the development and manufacture of injectable drugs, but also reinforce the competitive position of our clients in the global market,” said Oskar Gold, Vetter’s Senior Vice President Key Account Management, Marketing/Corporate Communications and Customer Project Management.
Compact serialization-ready manual workstation
11 Aug 2018
A cost-effective and space-saving solution for serializing cartons and performing multi-level aggregation on cases and pallets.Read more
Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines
8 Aug 2018
Company moves away from manual processing in favour of automated, scalable platforms.Read more
BASF receives award for its portfolio of natural cosmetic ingredients
7 Aug 2018
Company recognised for its innovation and continual delivery of new natural ingredients.Read more
Extended distribution agreement enables customers to continuously improve their bioprocesses
6 Aug 2018
Agreement includes Pall's next-generation Kaneka KanCapA 3G sorbent for the primary capture of mAbs from clarified cell culture.Read more
A new era for migraine patients
6 Aug 2018
EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.Read more
Amgen breaks ground on next-generation biomanufacturing plant in Rhode Island
3 Aug 2018
The plant will be first-of-its-kind in the US.Read more
Croda invests in SiSaf’s novel bio-courier technology
3 Aug 2018
ProSilic will give Croda’s customers access to the next generation of targeted and controlled drug delivery.Read more
Breast cancer device receives FDA approval
3 Aug 2018
The first non-radioactive, dual-tracer for sentinel lymph node biopsy approved in the US.Read more
Building contingency plans for an ambiguous post-Brexit market
31 Jul 2018
One company's positive approach to Brexit preparations, despite the lack of definition.Read more
Cherwell publishes guide on environmental monitoring processes and validation
31 Jul 2018
Supporting EM programs in preparation for proposed EU GMP Annex 1 changes.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation